Plain-English translation of NCT05656573 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new approach called for advanced prostate cancer. These are immune cells taken from your own body, engineered in a laboratory to recognize and attack prostate cancer cells, and then given back to you. The trial is designed to find the safest and most effective dose of this treatment.
Advanced prostate cancer often stops responding to standard treatments, leaving patients with limited options. This medication represents a new approach—using your own immune system as a targeted weapon against cancer cells—that may help when other treatments have failed.
You likely qualify if…
You likely don't qualify if…
You would first undergo blood tests and imaging to confirm your cancer expresses the target protein. Depending on which group you're assigned to, you may receive preparatory chemotherapy for 3 days to help prepare your immune system. Then you'll receive an infusion of your engineered immune cells on day zero. You'll be monitored closely afterward for side effects and to see how your body responds, with follow-up visits and blood tests to track your progress.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Nova Therapeutics LLC
Collaborators
Chinese PLA General Hospital
Enrollment target
~20 participants
Started
March 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
35 Years – 85 Years
Sex
Male only
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jay Zhang, MD/PhD
Nova Therapeutics LLC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.